Stoke Therapeutics, Inc. (STOK)
$
19.77
+0.47 (2.38%)
Key metrics
Financial statements
Free cash flow per share
1.0478
Market cap
1.1 Billion
Price to sales ratio
5.3099
Debt to equity
0
Current ratio
6.9799
Income quality
1.1736
Average inventory
0
ROE
0.1832
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing innovative antisense oligonucleotide (ASO) therapies aimed at addressing the root causes of severe genetic diseases in the United States. The company employs its proprietary Targeted Augmentation of Nuclear Gene Output technology to create ASOs that effectively enhance protein expression. Currently, its lead clinical candidate, STK-001, is undergoing a phase I/IIa clinical trial for the treatment of Dravet syndrome, a serious and progressive genetic epilepsy. In addition, STK-002 is in the preclinical stage, targeting autosomal dominant optic atrophy. Stoke Therapeutics has established a license and collaboration agreement with Acadia Pharmaceuticals Inc. to facilitate the discovery, development, and commercialization of novel RNA-based therapies for severe and rare genetic neurodevelopmental disorders affecting the central nervous system. Previously known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016, following its incorporation in 2014. The operating expenses amount to $137,927,000.00 encompassing various operational costs incurred. The gross profit ratio is 1.00 reflecting the efficiency of the company's production and sales operations. Moreover, the income before tax ratio is -2.43 which indicates the pre-tax margin. The weighted average number of shares outstanding is 54,008,883.00 highlighting the company's shareholder base. Lastly, the EBITDA ratio is -2.71 showcasing the company's operational efficiency. In the market spectrum, the stock is affordable at $12.06 making it an attractive option for budget-conscious investors. It has a notable average trading volume of 753,717.00 which indicates moderate liquidity for shareholders. With a market capitalization of $1,083,344,598.00 the company is classified as a small-cap player in the stock market. Stoke Therapeutics is a key player in the Biotechnology industry and contributes significantly to the overall market landscape. Additionally, it operates within the Healthcare sector, driving innovation and fostering growth in the biopharmaceutical field.
Is Stoke Therapeutics, Inc. (STOK) a good investment?
Investing in Stoke Therapeutics, Inc. (STOK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is Stoke Therapeutics, Inc. (STOK)'s stock forecast?
Analysts predict Stoke Therapeutics, Inc. stock to fluctuate between $5.35 (low) and $19.97 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Stoke Therapeutics, Inc.'s market capitalization?
As of 2025-08-29, Stoke Therapeutics, Inc.'s market cap is $1,083,344,598, based on 54,797,400 outstanding shares.
How does Stoke Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Stoke Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Stoke Therapeutics, Inc. (STOK) stock?
To buy Stoke Therapeutics, Inc. (STOK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STOK. Place an order (Market, Limit, etc.).
What is the best time to invest in Stoke Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Stoke Therapeutics, Inc. perform in the last earnings report?
Revenue: $36,555,000 | EPS: -$1.65 | Growth: -30.67%.
Where can I find Stoke Therapeutics, Inc.'s investor relations reports?
Visit https://www.stoketherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Stoke Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Stoke Therapeutics, Inc. stock?
All-time high: $33.06 (2021-11-22) | All-time low: $3.35 (2023-10-27).
What are the key trends affecting Stoke Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the following upcoming investor conferences: Cantor Global He.
prnewswire.com
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Stoke Therapeutics, Inc. (NASDAQ: STOK) on behalf of the company's shareholders. The investigation seeks to determine whether Stoke Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
zacks.com
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.46 per share a year ago.
businesswire.com
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednes.
seekingalpha.com
Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company's pipeline includes promising programs for SYNGAP-1, Rett syndrome, and ADOA, with industry validation via impressive new partnerships with Biogen and Acadia. Financially, Stoke is buoyed by its new milestone-rich deals, but as a ticker it faces high short interest and high volatility.
zacks.com
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year ago.
zacks.com
Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.
zacks.com
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
See all news
